6/19/2019 7:13:35 AM
Myriad Genetics Gets Second Insurance Reimbursement Decision For BRACAnalysis
5/7/2019 4:14:18 PM
Myriad Genetics Q3 Adjusted EPS $0.46 Vs $0.34 Last Year
4/9/2019 7:07:45 AM
Myriad Genetics Submits First Module Of Premarket Approval Application To FDA For MyChoice HRD CDx Test
2/5/2019 4:06:56 PM
Myriad Genetics Q2 EPS $0.03 Vs. $0.43 Year Ago
12/31/2018 7:07:15 AM
Myriad Genetics Says Former CEO Peter Durkee Meldrum, 71, Passed Away On December 20, 2018
12/26/2018 7:14:48 AM
Myriad Publishes Vectra Study In Journal Rheumatology
12/19/2018 7:09:13 AM
Myriad Genetics : EndoPredict Test Receives Positive NICE Recommendation For Patients With Early Breast Cancer
12/7/2018 8:33:34 AM
Myriad Genetics : Study Shows EndoPredict Can Guide Chemotherapy Decision For Women With Early-Stage Breast Cancer
11/19/2018 7:07:05 AM
Myriad Genetics To Repurchase $50 Mln Of Common Stock
11/12/2018 7:09:08 AM
Myriad To Present New Data From Portfolio Of Genetic Tests For Breast Cancer
11/6/2018 4:07:17 PM
Myriad Genetics Q1 Loss Per Share $0.01, Adjusted EPS $0.43
10/22/2018 7:24:12 AM
Myriad’s BRACAnalysis CDx Test Identifies Patients With Diagnosed Advanced Ovarian Cancer Who May Benefit From Lynparza
10/19/2018 7:07:35 AM
Myriad Genetics Announces New Data From Two Studies Of Vectra
10/16/2018 12:20:49 PM
Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Pfizer’s TALZENNA